If one of your goals for 2026 is to build wealth and be more financially secure, you’ll need to be intentional about how you spend your money. You can’t eliminate expenses entirely, but you can stop buying things that get in the way of reaching your financial goals. So, what are those purchases you should avoid. In a recent YouTube video, personal finance influencer Jaspreet Singh listed five things you shouldn’t buy if you want to stop wasting money. 1. Alcohol, Recreational Drugs and Cigarettes The f ...

Core Perspective - The recent executive order signed by President Trump reclassifies marijuana to a "Schedule III" drug, significantly changing its legal status and implications for the industry [2][5]. Industry Implications - The reclassification allows the $60 billion marijuana industry in the US to access banking services, which were previously restricted due to its "Schedule I" status [6][9]. - Wall Street is expected to become more involved in the marijuana sector, providing easier financing options for companies that handle marijuana, moving away from reliance on alternative funding methods [7][10]. Regulatory and Economic Benefits - A Schedule III classification enables safer regulation of marijuana, potentially reducing income for drug cartels and increasing tax revenues as the industry expands [11]. - The medical community may benefit from increased marijuana use as an alternative to opioids, which are more dangerous and addictive [11]. Political Context - The move is seen as politically advantageous for Trump, appealing to a demographic of single-issue voters who support marijuana legalization [13][14]. - Public perception of marijuana has shifted, with many Americans viewing it as less dangerous than alcohol, aligning with the president's decision [14].

Core Insights - President Trump signed an executive order to expedite the rescheduling of marijuana at the federal level, potentially reshaping the regulatory framework and recognizing its medical use [1][11] Executive Order Details - The executive order directs federal agencies to reclassify marijuana from Schedule I to Schedule III of the Controlled Substances Act (CSA) [2][11] - An executive order does not create new laws but instructs federal agencies to implement policy changes consistent with existing laws [3] Current Classification and Implications - Marijuana is currently classified as Schedule I, alongside substances like heroin, which are deemed to have no accepted medical use [4] - Reclassifying marijuana to Schedule III would align it with drugs recognized for medical use, such as ketamine and testosterone, which have a lower abuse risk [4] Medical Use and CBD Developments - The order emphasizes marijuana's legitimate medicinal uses, particularly as an alternative to opioid painkillers, while clarifying it does not legalize recreational use [5][11] - The executive order may also allow certain CBD-based products to be eligible for Medicare coverage by April 2026 if prescribed by a physician [5] Industry Impact - The executive order is seen as a significant regulatory milestone for the cannabis sector, which has long sought to remove marijuana from Schedule I [7] - Moving to Schedule III could alleviate tax burdens, improve profitability by eliminating IRS Rule 280E, and enhance research access and industry credibility [8] Cautionary Notes - Experts caution that the executive order may not be as transformative as anticipated, as it does not legalize marijuana federally or resolve state-federal law conflicts [9] - Access under Schedule III would remain strictly medical and prescription-based, with no pathway for recreational legalization or unrestricted sales [9] Market Reaction - The announcement has sparked renewed investor enthusiasm, with notable gains in cannabis stocks such as Tilray Brands, Canopy Growth Corporation, and Curaleaf Holdings [12] Future Considerations - The ultimate impact of the executive order will depend on the speed of agency actions, regulatory implementation, and Congressional follow-through, which has historically been inconsistent [13]

Core Points - President Donald Trump's decision to relax federal marijuana regulations has been positively received by the US cannabis industry, indicating a potential shift in federal policy towards cannabis [1] - Despite the regulatory changes, the cannabis sector continues to face significant challenges, particularly in accessing mainstream financial services and banking [1] Industry Summary - The US cannabis industry is experiencing a moment of optimism due to the relaxation of federal regulations, which may lead to increased investment and growth opportunities [1] - Access to traditional banking and financial services remains a critical issue for the cannabis sector, hindering its ability to operate on par with other industries [1]

Breaking news. It hasn't even been two hours since President Trump signed an executive order reclassifying marijuana. And the pot adjacent play, Scott's Miracle Grow, is making news regarding its Hawthorne subsidiary that sells cannabis growing supplies such as light systems and plant nutrients to marijuana growers.Scots talking about its plan to combine that subsidiary with a dedicated Pure Play cannabis company next year. Well, right there in the room, Scott's Miracle Grow CEO Jim Hagadorn was with the pr ...

With the stroke of his pen on Thursday afternoon, President Donald Trump directed federal officials to reclassify marijuana, loosening restrictions on the drug by signing an executive order in the name of driving medical research. “This reclassification order will make it far easier to conduct marijuana-related medical research, allowing us to study benefits, potential dangers and future treatments,” Trump told reporters in the Oval Office. (1) “It’s going to have a tremendously positive impact.” Must R ...

Today, I'm pleased to announce that I will be signing an executive order to reschedule marijuana from a schedule one to a schedule three control substance with legitimate medical uses. We have uh people begging for me to do this. People that are in great pain.For decades, this action has been requested by American patients suffering from extreme pain, incurable diseases, aggressive cancers, seizure disorders, neurological problems, and more, including numerous veterans with service related injuries and olde ...

Core Viewpoint - The president has signed an executive order to reclassify marijuana from a Schedule I drug to a Schedule III drug, indicating a shift towards less regulation and acknowledging the therapeutic potential of marijuana, particularly for patients with serious illnesses like cancer [1][2]. Industry Impact - The reclassification of marijuana is expected to have significant implications for the cannabis industry, potentially leading to increased investment and market activity as stocks have already begun to move positively in anticipation of this change [2]. Market Reaction - Following the announcement of the reclassification, cannabis stocks have been on the rise for about a week, indicating strong market interest and investor confidence in the sector's future prospects [2].

Core Point - The order being signed does not legalize marijuana or sanction its use as a recreational drug, emphasizing that it is not related to future legalization efforts [1] Group 1 - The statement highlights the distinction between the order and the legalization of marijuana, clarifying that it does not endorse recreational use [1]

Core Points - President Trump signed an executive order to reclassify marijuana as a Schedule III drug, easing some federal restrictions and allowing for more research opportunities [1][3] - The reclassification is aimed at addressing the medical needs of individuals suffering from extreme pain and incurable diseases, positioning marijuana as a substitute for opioid painkillers [2][4] - Marijuana stocks experienced a surge in value following rumors of the executive order prior to its announcement [3] Industry Impact - The reclassification could provide tax relief for marijuana businesses in states where the substance is already legalized, potentially boosting the industry [2] - Trump's campaign for a third term in 2024 indicates a shift towards a more favorable stance on marijuana, suggesting future legislative support for the industry [4][5] - The executive order does not fully legalize marijuana but represents a significant step towards more lenient regulations, which could enhance market conditions for marijuana-related businesses [1][4]